The interim data from the REGAIN trial, when presented on Nov. 16, could provide the first clinical evidence of Alpha DaRT's safety and feasibility in glioblastoma. Positive results may support further development and eventual regulatory pathways, while negative results could slow the pipeline. Monitor the call and any subsequent press releases for specific efficacy and safety data.
Drug in focus
DRTS drug pipeline →Alpha DaRT
▲ Bullish Named in this 6-K- Impact
- Phase
- Pivotal (PMA submission ongoing for cSCC); Phase 2 pilot for glioblastoma (REGAIN); Pilot for pancreatic cancer (IMPACT)
- Time to market
- The ReSTART pivotal trial for recurrent cSCC completed enrollment in May 2026 and the first PMA module was submitted in January 2026. If the modular PMA process proceeds smoothly, a US approval decision could come in late 2027 or 2028. Alpha DaRT already has marketing approval in Japan for head and neck cancer and in Israel for SCC of the skin and oral cavity.
- Next catalyst
- None dated
What to watchThe REGAIN interim data (all 8 patients alive, median survival not reached at 6.9 months follow-up) was released Nov 15, with an investor call on Nov 16. The next major catalyst is the IMPACT pancreatic cancer pilot study data expected in early 2027, and continued progress on the modular PMA submission for cSCC. Q3 2026 earnings are scheduled for Nov 24. Watch for any PMA submission completion announcements for cSCC, which would mark the clearest path to a US approval decision.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 12 $13.36entry
- T+1 · 4d ago +0.15%α +0.51% · $13.38
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Alpha Tau Medical Ltd. filed a Form 6-K announcing a conference call and webcast on Nov. 16, 2026, to discuss new interim results from the REGAIN trial of Alpha DaRT in recurrent glioblastoma, following a presentation at the SNO conference. The filing contains no periodic financial results, so it is analyzed as a clinical/regulatory event rather than an earnings release.
Key Facts
- Alpha Tau will host an investor call on Nov. 16, 2026 to discuss new interim results from the REGAIN trial (Alpha DaRT in recurrent glioblastoma).
- The call follows presentation of data at the 31st Annual SNO meeting (Nov. 12-15, 2026).
- REGAIN is a U.S. multicenter trial expected to enroll up to 20 patients with recurrent glioblastoma not amenable to surgical resection.
- Primary objective is to evaluate feasibility and safety of Alpha DaRT in this setting.
- Alpha DaRT has marketing approval in Japan for head and neck cancer and in Israel for SCC of skin and oral cavity, but not for glioblastoma.
Financial Impact
No financial figures disclosed; the event is a clinical data update with no stated revenue, cost, or deal value.
Risk Factors
- Interim data from a small (up to 20-patient) single-arm trial may not be predictive of final results or regulatory success.
- Alpha DaRT has not been approved for glioblastoma; regulatory path is uncertain.
- The company has significant losses and may need additional funding.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-118478 |
| Document: ea031155201ex99-1.htm | 0001213900-26-118478 |
| Document: 0001213900-26-118478-index-headers.html | 0001213900-26-118478 |
| Document: 0001213900-26-118478-index.html | 0001213900-26-118478 |
| Document: 0001213900-26-118478.txt | 0001213900-26-118478 |
| Earnings Context (Synthetic; results releases only) | 0001213900-26-118478 |
Track record
25 reports on DRTS
9 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +68.80% at T+60 after the Apr 23, 2026 report. 12 of 13 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry $14.50 Now $11.97 −17.45% settles Feb 12
- Nov 16, 2026today 6-K Bullish 6/10 Entry $15.46 Now $11.97 −22.56% settles Feb 12
- Nov 15, 20261d ago Press Release Bullish 7/10 Entry $13.35 Now $11.97 −10.34% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 3/10 Viewing Entry $13.36 Now $11.97 −10.40% settles Feb 10
- Oct 29, 202618d ago 6-K Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 22, 202625d ago 6-K Neutral 4/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 22, 202625d ago Press Release Neutral 3/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 19, 202628d ago 6-K Bullish 6/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers